We are a global leader

for rapid reliable Urea Breath Tests for diagnosing the stomach ulcer bacterium Helicobacter pylori.

LATEST NEWS

All news
October 14 | 2025

Meet Kibion at JFBM

Kibion will exhibit at JFBM October 5 – 7, 2022 in St Etienne, France. Please come and visit us on booth 38. We will be happy to demonstrate our product with you.

+
October 14 | 2025

At vero eos et accusam

At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet.

+

The company

Kibion is a global leader in complete solutions for rapid reliable Urea Breath Tests for diagnosing the stomach ulcer bacterium Helicobacter pylori.

In 2011 Orexo acquired the German company Wagner Analysen Technik GmbH, a leading manufacturer of IRIS™ instruments for analyzing diagnostic breath tests. Integrating these two businesses transformed Kibion into a complete solutions provider of diagnostic breath tests and instrumentation, and a leading player in Helicobacter pylori testing.

The 30th of April 2015, Kibion was acquired by a team of Swedish investors and business developers. Through this investment Kibion will strengthen its operations and continue to grow.

The 30th of September 2016, Kibion was acquired by the French company Laboratory Mayoly Spindler. This acquisition will strengthen both companies’ global and generate outstanding synergies. Kibion is now successfully integrated into the Mayoly Group.

Our history

Kibion was founded in 2005, as a subsidiary of the Swedish pharmaceutical company Orexo AB, to create a clear focus for exploiting breakthrough discoveries in the diagnosis of Helicobacter pylori.

In 2011 Orexo acquired the German company Wagner Analysen Technik GmbH, a leading manufacturer of IRIS™ instruments for analyzing diagnostic breath tests. Integrating these two businesses transformed Kibion into a complete solutions provider of diagnostic breath tests and instrumentation, and a leading player in Helicobacter pylori testing.

The 30th of April 2015, Kibion was acquired by a team of Swedish investors and business developers. Through this investment Kibion will strengthen its operations and continue to grow.

Innovative solutions

H. pylori infection is the major cause of ulcer disease and gastritis worldwide, which is often present as gnawing or burning epigastric pain. Designated as a carcinogen by the World Health Organization, H. pylori infection is the strongest known risk factor for non-cardia gastric adenocarcinoma. Infected people have a 2–6-fold increased risk of developing gastric cancer and mucosal associated-lymphoid-type (MALT) lymphoma compared with their uninfected counterparts.

UBT is the most investigated and best recommended non-invasive test in the context of a ‘test-and-treat strategy.

The 13C-UBT is widely employed for the diagnosis of H. pylori infection as well as to verify successful eradication after treatment.

Kibion, whose name originates from the old Nordic “Kibi” meaning smart and alert, offers innovative yet trustworthy solutions. The company currently supplies test systems and high-quality instruments to diagnose Helicobacter pylori infections. In addition, it continuously evaluates new business opportunities within its field of operations.

Our Global Network

Click on the dot to contact us based on your geographic location

Kibion GmbH in Bremen, Germany, is dedicated to supporting all customers.
We will all do our best to answer your queries.

Contact us for: